Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.72 |
| ▸ | HTT | P42858 | 7/20 | 0.72 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.72 |
| ▸ | TP53 | P04637 | 6/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.72 |
| ▸ | USP2 | O75604 | 3/20 | 0.72 |
| ▸ | COMT | P21964 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.54 |
| ▸ | CCR1 | P32246 | 2/20 | 0.54 |
| ▸ | CCR8 | P51685 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MMP14 | P50281 | 3/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tilbroquinol SCHEMBL1441958 | 1.00 | KDM4E (0.72) | KDM4EHTTHSP90AA1TP53SMN1; SMN2 | |
| SCHEMBL13283110 | 0.86 | HSP90AA1 (0.72) | KDM4EHTTHSP90AA1TP53SMN1; SMN2 | |
| Broxyquinoline SCHEMBL115293 | 0.84 | KDM4E (1.00) | KDM4EHTTHSP90AA1TP53SMN1; SMN2 | |
| SCHEMBL318630 | 0.84 | HTT (0.59) | KDM4EHTTHSP90AA1TP53SMN1; SMN2 | |
| SCHEMBL29577465 | 0.84 | HTT (0.59) | KDM4EHTTHSP90AA1TP53SMN1; SMN2 | |
| SCHEMBL17046868 | 0.84 | HTT (0.59) | KDM4EHTTHSP90AA1TP53SMN1; SMN2 | |
| Broxyquinoline SCHEMBL30485535 | 0.84 | KDM4E (1.00) | KDM4EHTTHSP90AA1TP53SMN1; SMN2 | |
| Broxyquinoline SCHEMBL29607319 | 0.84 | KDM4E (1.00) | KDM4EHTTHSP90AA1TP53SMN1; SMN2 | |
| Broxyquinoline SCHEMBL31157810 | 0.82 | KDM4E (0.96) | KDM4EHTTHSP90AA1TP53SMN1; SMN2 | |
| Broxyquinoline SCHEMBL22734870 | 0.82 | KDM4E (0.96) | KDM4EHTTHSP90AA1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367232-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | HUTCHINSON FRED CANCER RES (US) | 2025-12-04 | — | — | US | disclosed |
| US-12203124-B2 | Methods for improved rapid antimicrobial susceptibility testing | SeLux Diagnostics, Inc. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12016880-B2 | Halogen treatment of heart attack and ischemic injury | FRED HUTCHINSON CANCER CENTER (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3104939-B1 | TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY WITH SODIUM IODIDE | FRED HUTCHINSON CANCER CENTER (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3347343-B1 | AZETIDINIMINES AS CARBAPENEMASES INHIBITORS | CENTRE NAT RECH SCIENT (FR) | 2023-09-27 | — | — | EP | disclosed |
| US-11649477-B2 | Assays and reagents for antimicrobial susceptibility testing | SeLux Diagnostics, Inc. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-109072280-B | Method for rapid antimicrobial sensitivity testing | 赛录科试诊断公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20220313730-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | FRED HUTCHINSON CANCER CENTER | 2022-10-06 | — | — | US | disclosed |
| US-11339418-B2 | Antimicrobial susceptibility testing and microbial identification | SeLux Diagnostics, Inc. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11285133-B2 | 2- or 3-imidazolines as carbapenemases inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12203124-B2 | Methods for improved rapid antimicrobial susceptibility testing | AMPD3, AMPD1, AMPD2 | KDM4E 4444/4885HTT 3276/4885HSP90AA1 127/4885 |
| US-11285133-B2 | 2- or 3-imidazolines as carbapenemases inhibitors | PADI3, PADI1, RPIA | KDM4E 1162/4885HTT 4767/4885HSP90AA1 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.